title: Autologous stem cell transplantation for the treatment of neuroblastoma in Korea.
abstract: Autologous stem cell transplantation (ASCT) for the treatment of high-risk neuroblastoma (NBL) is an accepted method for restoring bone marrow depression after high dose chemotherapy. We retrospectively analyzed eighty eight cases of NBL that underwent ASCT following marrow ablative therapy at 12 transplant centers of the Korean Society of Pediatric Hematology-Oncology between January 1996 and September 2000. Seventy nine children were of stage IV NBL and 9 were of stage III with N-myc amplification. Various cytoreductive regimens were used. However, the main regimen was 'CEM' consisting of carboplatin, etoposide and melphalan, and this was used in 66 patients. Total body irradiation was also added in 36 patients for myeloablation. To reduce tumor cell contamination, stem cell infusions after CD34+ cell selection were performed in 16 patients. Post-transplantation therapies included the second transplantation in 18 patients, interleukin2 therapy in 45, 13-cis retinoic acid in 40, 131-meta-iodobenzylguanidine in 4, conventional chemotherapy in 11, and local radiotherapy in 8. Twenty two patients died, sixty six patients are surviving 1 to 46 months after ASCT (median followup duration, 14.5 months). Although the follow-up period was short and the number of patients small, we believe that ASCT might improve the survival rate in high-risk NBL.
authors.affiliation: Department Pediatrics, College of Medicine, Seoul National University Children's Hospital, 28 Yongon-dong, Chongno-gu, Seoul, Korea.
authors.forename: Kyung Ha
authors.initials: KH
authors.lastname: Ryu
authors.forename: Hyo Seop
authors.initials: HS
authors.lastname: Ahn
authors.forename: Hong Hoe
authors.initials: HH
authors.lastname: Koo
authors.forename: Hoon
authors.initials: H
authors.lastname: Kook
authors.forename: Moon Kyu
authors.initials: MK
authors.lastname: Kim
authors.forename: Hack Ki
authors.initials: HK
authors.lastname: Kim
authors.forename: Thad
authors.initials: T
authors.lastname: Ghim
authors.forename: Hyung Nam
authors.initials: HN
authors.lastname: Moon
authors.forename: Jong Jin
authors.initials: JJ
authors.lastname: Seo
authors.forename: Ki Woong
authors.initials: KW
authors.lastname: Sung
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Shin
authors.forename: Eun Sun
authors.initials: ES
authors.lastname: Yoo
authors.forename: Chuhl Joo
authors.initials: CJ
authors.lastname: Lyu
authors.forename: Young Ho
authors.initials: YH
authors.lastname: Lee
authors.forename: Hahng
authors.initials: H
authors.lastname: Lee
authors.forename: Bin
authors.initials: B
authors.lastname: Cho
authors.forename: Hyun Sang
authors.initials: HS
authors.lastname: Cho
authors.forename: Hyung Soo
authors.initials: HS
authors.lastname: Choi
authors.forename: Jeong Ok
authors.initials: JO
authors.lastname: Hah
authors.forename: Tai Ju
authors.initials: TJ
authors.lastname: Hwang
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007723:Korea; D008297:Male; D019653:Myeloablative Agonists / Q000627:therapeutic use; D009447:Neuroblastoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D015996:Survival Rate; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D019653:Myeloablative Agonists